[go: up one dir, main page]

FR2824326B1 - Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications - Google Patents

Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications

Info

Publication number
FR2824326B1
FR2824326B1 FR0105980A FR0105980A FR2824326B1 FR 2824326 B1 FR2824326 B1 FR 2824326B1 FR 0105980 A FR0105980 A FR 0105980A FR 0105980 A FR0105980 A FR 0105980A FR 2824326 B1 FR2824326 B1 FR 2824326B1
Authority
FR
France
Prior art keywords
papillomavirus
peptides
proteins
applications
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0105980A
Other languages
English (en)
Other versions
FR2824326A1 (fr
Inventor
Bernard Maillere
Villada Isabelle Bourgault
Moratille Sandra Pouvelle
Jean Gerard Guillet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0105980A priority Critical patent/FR2824326B1/fr
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Priority to PCT/FR2002/001533 priority patent/WO2002090382A2/fr
Priority to EP02730391A priority patent/EP1383535A2/fr
Priority to CA 2446062 priority patent/CA2446062A1/fr
Priority to US10/476,570 priority patent/US7488791B2/en
Priority to AU2002302713A priority patent/AU2002302713A1/en
Priority to JP2002587459A priority patent/JP2005505503A/ja
Publication of FR2824326A1 publication Critical patent/FR2824326A1/fr
Application granted granted Critical
Publication of FR2824326B1 publication Critical patent/FR2824326B1/fr
Priority to US12/347,471 priority patent/US20100203080A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
FR0105980A 2001-05-04 2001-05-04 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications Expired - Fee Related FR2824326B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR0105980A FR2824326B1 (fr) 2001-05-04 2001-05-04 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
EP02730391A EP1383535A2 (fr) 2001-05-04 2002-05-03 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
CA 2446062 CA2446062A1 (fr) 2001-05-04 2002-05-03 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
US10/476,570 US7488791B2 (en) 2001-05-04 2002-05-03 Mixture of peptides derived from E6 and/or E7 papillomavirus proteins and uses thereof
PCT/FR2002/001533 WO2002090382A2 (fr) 2001-05-04 2002-05-03 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
AU2002302713A AU2002302713A1 (en) 2001-05-04 2002-05-03 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof
JP2002587459A JP2005505503A (ja) 2001-05-04 2002-05-03 Ｅ６及び／又はｅ７パピローマウイルスタンパク質に由来するペプチドの混合物並びにその使用
US12/347,471 US20100203080A1 (en) 2001-05-04 2008-12-31 Mixture of Peptides Derived from E6 and/or E7 Papillomavirus Proteins and Uses Thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0105980A FR2824326B1 (fr) 2001-05-04 2001-05-04 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications

Publications (2)

Publication Number Publication Date
FR2824326A1 FR2824326A1 (fr) 2002-11-08
FR2824326B1 true FR2824326B1 (fr) 2004-03-19

Family

ID=8862980

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0105980A Expired - Fee Related FR2824326B1 (fr) 2001-05-04 2001-05-04 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications

Country Status (7)

Country Link
US (2) US7488791B2 (fr)
EP (1) EP1383535A2 (fr)
JP (1) JP2005505503A (fr)
AU (1) AU2002302713A1 (fr)
CA (1) CA2446062A1 (fr)
FR (1) FR2824326B1 (fr)
WO (1) WO2002090382A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
DE10336916B4 (de) * 2003-08-07 2015-02-19 Danfoss A/S Regelventil und Wärmetauscheranordnung
US7576323B2 (en) * 2004-09-27 2009-08-18 Johns Hopkins University Point-of-care mass spectrometer system
JP2008044848A (ja) * 2004-11-30 2008-02-28 Univ Kurume Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
ES2310072B1 (es) * 2005-12-23 2009-11-16 Proyecto De Biomedicina Cima, S.L. Nuevos peptidos determinantes antigenicos t colaboradores (/dth).
US8865162B2 (en) * 2008-06-13 2014-10-21 Oncohealth Corp. Monoclonal antibodies against HPV proteins
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
JP6035503B2 (ja) 2007-05-31 2016-11-30 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク ワクチンで使用するための、子宮頸部悪性腫瘍に浸潤するｔ細胞によって標的とされるｈｐｖエピトープ
AU2013205259B2 (en) * 2007-05-31 2015-06-11 Isa Pharmaceuticals B.V. HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
KR20090103571A (ko) * 2008-03-28 2009-10-01 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
US9789129B2 (en) 2008-04-17 2017-10-17 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
JP2012526286A (ja) 2009-05-07 2012-10-25 オンコヘルス コーポレーション ヒトパピローマウイルス（ｈｐｖ）およびｈｐｖ関連癌の初期段階および後期段階の検出、スクリーニング、および診断のための高度または≧ｃｉｎ２の同定
AR074485A1 (es) * 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
WO2011084598A1 (fr) 2010-01-08 2011-07-14 Oncohealth Corporation Immunoessais sur le vph à base de cellule et à haut débit pour diagnostiquer et dépister des cancers associés au vph
CN102060929A (zh) * 2010-06-07 2011-05-18 夏书奇 T细胞免疫平衡肽
EA025152B1 (ru) 2010-12-02 2016-11-30 Бионор Иммуно Ас Конструкция пептидного каркаса
EP3632464A1 (fr) 2012-06-15 2020-04-08 PDS Biotechnology Corporation Compositions de vaccins comportant des lipides cationiques et leurs procédés d'utilisation
AU2013317805B2 (en) 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1
EP3058956A1 (fr) 2015-02-23 2016-08-24 Institut Curie Vaccination/radiothérapie combinée pour le traitement du cancer
CA3005251A1 (fr) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipides en tant que vecteurs synthetiques pour ameliorer le traitement et la presentation de l'antigene ex-vivo en therapie cellulaire dendritique
EP3471758A1 (fr) 2016-06-20 2019-04-24 ISA Pharmaceuticals B.V Formulation d'un vaccin peptidique.
EP3267119A1 (fr) 2016-07-07 2018-01-10 E.ON Sverige AB Système de chauffage et de refroidissement combiné
JP7165652B2 (ja) * 2016-10-05 2022-11-04 ピーディーエス バイオテクノロジー コーポレイション 新規ｈｐｖ１６非ｈｌａ拘束性ｔ細胞ワクチン、その組成物及び使用方法
WO2019145792A1 (fr) * 2018-01-24 2019-08-01 The Council Of The Queensland Institute Of Medical Research Immunothérapie de l'hpv
EP3784688A2 (fr) * 2018-04-26 2021-03-03 Agenus Inc. Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
WO2020112720A1 (fr) * 2018-11-28 2020-06-04 The General Hospital Corporation Vaccins anticancéreux dirigés contre les lymphocytes t contre des virus commensaux
EP4281106A4 (fr) * 2021-01-21 2024-12-25 The General Hospital Corporation Vaccins anticancéreux ciblant des lymphocytes t contre des virus commensaux pour le traitement de carcinomes muqueux
WO2024223299A2 (fr) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Procédés de traitement du cancer par administration de compositions immunogènes et d'un inhibiteur de pd-1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
DE69232963T2 (de) * 1991-07-13 2004-03-04 Dade Behring Marburg Gmbh Verwendung von HPV-16 E6 und E7-Gen gewonnen Peptiden für den diagnostischen Zweck
RS50101B (sr) * 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
CA2317724A1 (fr) * 1998-01-09 1999-07-15 Circassia Limited Procedes et compositions de desensibilisation
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
CA2377525A1 (fr) * 1999-07-19 2001-03-29 Epimmune, Inc. Induction de reponses immunitaires cellulaires au virus de l'hepatite c mettant en oeuvre des compositions de peptides et d'acide nucleique
SE9903031D0 (sv) * 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
DE60042556D1 (de) * 1999-09-16 2011-02-10 Eisai Inc Für polyepitop-polypeptide kodierende nukleinsäuren
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
JP4873810B2 (ja) * 1999-10-05 2012-02-08 エピミューン インコーポレイテッド ペプチドおよび核酸組成物を使用する、ヒト免疫不全ウイルス−１に対する細胞性免疫応答の誘導

Also Published As

Publication number Publication date
US7488791B2 (en) 2009-02-10
AU2002302713A1 (en) 2002-11-18
WO2002090382A2 (fr) 2002-11-14
US20100203080A1 (en) 2010-08-12
FR2824326A1 (fr) 2002-11-08
CA2446062A1 (fr) 2002-11-14
US20040170644A1 (en) 2004-09-02
JP2005505503A (ja) 2005-02-24
EP1383535A2 (fr) 2004-01-28
WO2002090382A3 (fr) 2003-10-02

Similar Documents

Publication Publication Date Title
FR2824326B1 (fr) Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
EP1549768A4 (fr) Cristallographie de proteines microfluidiques
HUE044812T2 (hu) Prolinspecifikus endoproteázok alkalmazása peptidek és fehérjék hidrolízisére
DE60101853D1 (de) Schaltungsunabhängige transformation von sensorkonfigurationen zur klassifizierung von personen
EP1424392A4 (fr) Nouvelles proteines de secretion et adn associe
AU2002351239A8 (en) Antibody to latent membrane proteins and uses thereof
AU2003253784A1 (en) Peptides from the e2, e6 and e7 proteins of human papillomaviruses 16 and 18 for detecting and/or diagnosing cervical and other cancers
EP1711650A4 (fr) Techniques de cristallographie de proteines microfluidiques
FR2835829B1 (fr) Nouveau procede de preparation de biopuces a adn ou a proteines et leurs applications
WO2000053776A3 (fr) Nouveaux genes humains du type kallikreine
DE60232862D1 (de) Rekombinantes pockenvirus für chimäre proteine des menschlichen immunschwächevirus
DE60215133D1 (de) Abscheidung von löslichen materialien
AU2002362604A1 (en) Novel molecules of the pyrin domain protein family and uses thereof
IL160396A0 (en) Nucleic acids and proteins of insect or83b odorant receptor genes and uses thereof
EP1432448A4 (fr) Nouvelles molecules de la famille de proteines associee a la hkid-1 et utilisations desdites molecules
IL158860A0 (en) Nucleic acids and corresponding proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer and pharmaceutical compositions containing the same
AU2002355571A1 (en) Nucleic acid sensor molecules and methods of using same
AU1572702A (en) Novel immunomodulatory protein and useful embodiments thereof
EP1383907A4 (fr) Proteines proteasiques humaines isolees, molecules d'acides nucleiques codant pour ces proteines proteasiques humaines et utilisations associees
AU2001273287A1 (en) Large scale expression and purification of recombinant proteins
FR2820425B1 (fr) Melange de peptides issus d'une proteine nef et leurs applications
AU2001229697A1 (en) Novel molecules of the card-related protein family and uses thereof
AU2002323612A1 (en) Novel clark protein and nucleic acid molecules and uses therefor
ATE506433T1 (de) Prozessierung von peptiden und proteinen
EP1842857A4 (fr) Proteines mutantes de l'interferon et leur utilisation

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140131